Compare NWL & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWL | IRON |
|---|---|---|
| Founded | 1903 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.4B |
| IPO Year | 1995 | 2020 |
| Metric | NWL | IRON |
|---|---|---|
| Price | $5.62 | $61.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $6.66 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 5.1M | 591.6K |
| Earning Date | 10-30-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $14,742,200,000.00 | N/A |
| Revenue This Year | $1.75 | N/A |
| Revenue Next Year | $1.48 | N/A |
| P/E Ratio | $33.20 | ★ N/A |
| Revenue Growth | ★ 11.14 | N/A |
| 52 Week Low | $3.07 | $40.00 |
| 52 Week High | $7.13 | $99.50 |
| Indicator | NWL | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 29.13 |
| Support Level | $4.95 | $58.30 |
| Resistance Level | $6.28 | $82.89 |
| Average True Range (ATR) | 0.19 | 2.50 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 66.90 | 28.02 |
Newell Brands Inc is an American consumer goods company with a portfolio of brands, including Rubbermaid, Sharpie, Graco, Coleman, Rubbermaid Commercial Products, Yankee Candle, Paper Mate, FoodSaver, Dymo, EXPO, Elmer's, Oster, NUK, Spontex and Campingaz. The group is focused on delighting consumers by lighting up everyday moments. Its segments are Home and Commercial Solutions, Learning and Development, and Outdoor and Recreation. The group geographic areas are the United States, Canada, Europe, the Middle East and Africa, Asia Pacific, and Latin America.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.